LipoCurc (liposomal curcumin) / Signpath Pharma - LARVOL DELTA

Curcumin as a palliative treatment for malignant pleural effusion (ANZCTR) - P1 | N=9 | Withdrawn | Sponsor: Flinders University | Recruiting ➔ Withdrawn

Trial withdrawal • Palliative care • Respiratory Diseases

A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer (clinicaltrials.gov) - P1/2 | N=30 | Completed | Sponsor: SignPath Pharma, Inc. | Active, not recruiting ➔ Completed

Trial completion • Oncology

Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE). (PubMed, BMJ Open) - "Participants will be administered a single dose of liposomal curcumin (LipoCurc, SignPath Pharma) via their existing TIPC as a sequential enrolling case series with the following dose cohorts: 100, 200 and 300 mg/m...ACTRN12620001216909. V.1.0."

Clinical • Journal • P1 data • Pleural effusion • Oncology • Palliative care • Respiratory Diseases • Thoracic Cancer